Insider Selling: Natera (NASDAQ:NTRA) Director Sells $1,099,080.00 in Stock

Natera, Inc. (NASDAQ:NTRA) Director Roy Baynes sold 5,112 shares of the firm’s stock in a transaction that occurred on Wednesday, November 19th. The stock was sold at an average price of $215.00, for a total transaction of $1,099,080.00. Following the sale, the director directly owned 18,359 shares of the company’s stock, valued at $3,947,185. The trade was a 21.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Natera Price Performance

NTRA traded up $5.08 during trading on Friday, hitting $230.63. The company had a trading volume of 2,870,319 shares, compared to its average volume of 1,609,609. Natera, Inc. has a 1-year low of $125.38 and a 1-year high of $235.89. The company has a market cap of $31.83 billion, a PE ratio of -100.71 and a beta of 1.75. The business has a 50-day moving average of $186.27 and a 200-day moving average of $167.81.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The company had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.Natera’s revenue was up 34.7% on a year-over-year basis. During the same period in the prior year, the business earned ($0.26) earnings per share. Research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on NTRA shares. BNP Paribas upgraded Natera to a “hold” rating and set a $172.00 price objective on the stock in a research note on Monday, October 27th. Morgan Stanley boosted their price target on Natera from $195.00 to $220.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Piper Sandler upped their price target on Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. UBS Group raised their price objective on Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Royal Bank Of Canada set a $268.00 target price on shares of Natera and gave the company an “outperform” rating in a research note on Tuesday, September 2nd. Fifteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $220.29.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NTRA. Allianz Asset Management GmbH lifted its stake in Natera by 179.2% in the first quarter. Allianz Asset Management GmbH now owns 251,883 shares of the medical research company’s stock valued at $35,619,000 after buying an additional 161,672 shares during the last quarter. HighPoint Advisor Group LLC grew its position in shares of Natera by 30.8% during the first quarter. HighPoint Advisor Group LLC now owns 1,986 shares of the medical research company’s stock worth $308,000 after acquiring an additional 468 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in shares of Natera by 4.8% in the 1st quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 127,181 shares of the medical research company’s stock worth $17,985,000 after acquiring an additional 5,831 shares during the period. Bank Julius Baer & Co. Ltd Zurich bought a new stake in Natera in the 1st quarter valued at about $701,000. Finally, KLP Kapitalforvaltning AS boosted its stake in Natera by 83.2% during the 1st quarter. KLP Kapitalforvaltning AS now owns 43,600 shares of the medical research company’s stock valued at $6,165,000 after purchasing an additional 19,800 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.